New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
09:28 EDTRPRXRepros granted end of Phase 2 meeting in late May for Proellex-V by FDA
Repros Therapeutics announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application. Once the meeting is held, the company will report the outcome to the financial community in a timely fashion.
News For RPRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
09:17 EDTRPRXOn The Fly: Pre-market Movers
Subscribe for More Information
October 16, 2014
20:03 EDTRPRXRepros Therapeutics upcoming meeting with FDA to be Type C, not Type B
Subscribe for More Information
07:41 EDTRPRXRepros Therapeutics management to meet with Brean Capital
Subscribe for More Information
October 13, 2014
12:33 EDTRPRXOptions with increasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use